Donepezil + Estrogen + Progesterone
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease
Conditions
Alzheimer Disease
Trial Timeline
Sep 1, 1999 → Mar 1, 2004
NCT ID
NCT00006399About Donepezil + Estrogen + Progesterone
Donepezil + Estrogen + Progesterone is a phase 2 stage product being developed by Eisai for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00006399. Target conditions include Alzheimer Disease.
What happened to similar drugs?
20 of 20 similar drugs in Alzheimer Disease were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00006399 | Phase 2 | Completed |
Competing Products
20 competing products in Alzheimer Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 21 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 32 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 40 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 35 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 35 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 35 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 47 |
| GSK4527226 | Alector | Phase 2 | 29 |
| AL002 + Placebo | Alector | Phase 2 | 25 |
| GSK4527226 | Alector | Phase 2 | 32 |
| AL002 | Alector | Phase 2 | 17 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| donanemab | Eli Lilly | Phase 2 | 35 |
| ATH-1017 | LeonaBio | Phase 2/3 | 20 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 28 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 25 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 19 |
| simufilam | Cassava Sciences | Phase 2 | 17 |
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 19 |